In the great state of Tennessee, there is a company that is on the cutting edge of cancer research and has taken their technology worldwide in an attempt to help cure the disease. The company is Provectus Pharmaceuticals and if they achieve continued success, they may soon be a well known name.

Provectus Pharmaceuticals is a development-stage oncology and dermatology biopharmaceutical company which uses the agent PV-10 as a therapeutic agent for a broad spectrum of cancers. Currently, PV-10 is available for select cancer patients in the U.S. but the program was initiated in Australia in June of 2009 and has excelled across the globe.

In the U.S., the PV-10 program commenced at St. Luke’s Hospital and Health Network in Bethlehem, PA under the watchful eye of the renowned Dr. Sanjiv Agarwaia who served as the Principal Investigator at that site for the Phase 2 Melanoma Trial. The U.S.

Companies featured in this edition of the newsletter: ACTC, CHIP, CUR, CVM, ENZ, IMUC, IWEB, SRCO, SVUL, XSNX

Markets finally snapped their winning streak last week, as weakness in housing markets and durable goods orders led to broad-based declines in all of the major indices. All told, the Dow surrendered 155 points on the week to close at 9665, down 1.6% on the week but up 10.1% on the year. The Nasdaq lost 2.0% on the week to close at 2090, up 32.6% on the year, while the S&P 500 and Russell 2000 posted losses of 2.2% and 3.1% respectively, paring their yearly gains to 15.6% and 19.9%.

Unexpectedly poor data from the housing sector was the big economic story on the week as both new and existing August home sales failed to live up to expectations. New home sales increased modestly to 429,000, falling short of estimates calling

Provectus Pharmaceuticals Inc. is quickly gaining a reputation as an up-and-coming development-stage oncology and dermatology biopharmaceutical company. Helping to enhance this reputation and its position in the marketplace, Provectus announced the addition of Mount Sinai School of Medicine as the second and final site for its expanded Phase 2 clinical trial of the company’s lead dermatology agent PH-10 for psoriasis. Jason Elmer, M.D., who served as the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis of which patent enrollment was completed in June, will also serve as the principal investigator of this trial.

Commenting on the value of Dr. Elmer’s work on this project, Provectus CEO Craig Dees, Ph.D. stated, “Dr. Emer’s work with PH-10 for atopic dermatitis, his involvement in the ongoing research of the product as a dermatological therapy, and Mount Sinai School of Medicine’s outstanding reputation in dermatological research make this

Stock-PR OTC Stock Report August 18, 2009

Insight Management Corporation (OTCBB: ISIM) President and CEO, Jennifer Rapacki, August 18, 2009 commented on positive trends in the domestic natural gas services market. “While existing natural gas wells continue to demand maintenance, new drilling activity should create added demands for service,” Ms. Rapacki noted. “We are now seeing an increase in leasing activity and are very encouraged about how that will translate into higher revenues for service companies like ours in the remainder of this year.”

Sector 10, Inc. (OTCBB:SECI) (Frankfurt:4SR) announced that it has submitted proposals to multiple cities regarding the deployment of the Pilot PLX-3D system. The proposals were sent in response to inquiries received from the announcement of the Pilot PLX-3D deployment program in the July 21, 2009 press release. The PLX-3D deployment and the related installation of SRU’s are designed to help communities better prepare for emergencies, disasters and

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

Tuesday August 18, 2009

PennyOmega.com Stock Report!

**************************************************************

Provectus Pharmaceuticals, Inc. (OTCBB:PVCT), a development-stage oncology and dermatology biopharmaceutical company, has added Mount Sinai School of Medicine as its second and final site for its expanded Phase 2 clinical trial of the Company’s lead dermatology agent PH-10 for psoriasis. Jason Emer, M.D. will serve as principal investigator of the trial; he is also the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis, for which patient enrollment was completed in June.

Consistent with its ongoing efforts to enhance services offered to its customers and contract services clients, SouthWest Water Company (NASDAQ:SWWC), a leading provider of